The year 2025 marked a significant period for India's pharmaceutical sector, demonstrating resilience and scientific ambition amidst geopolitical uncertainty. The industry, now valued at $55 billion and growing over 10% annually, aims for $100 billion by 2030. Exports exceeded $30 billion, reinforcing India's role as a major global supplier of generics and vaccines. A proposed 100% US tariff on imported patented drugs served as a strategic alert, prompting Indian companies to accelerate diversification into new markets and explore manufacturing footprints abroad.